Ra Pharmaceuticals, Inc. (RARX)


Stock Price Forecast

April 1, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Ra Pharmaceuticals, Inc. chart...

About the Company

Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA.

Sector

Health Technology

Industry

Pharmaceuticals: Major

Employees

89

CEO

Douglas A. Treco

Exchange

NASDAQ

Website

http://www.rapharma.com

$3M

Total Revenue

89

Employees

$2B

Market Capitalization

-20.78

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $RARX News

13 Best Biotech Stocks To Buy Under $20

5d ago, source:

At just $1.38 per share, Gossamer Bio Inc (NASDAQ:GOSS) is the least expensive in the list of best biotech stocks to buy ...

5 Stocks that Analysts Love in March 2024

15h ago, source: TipRanks on MSN

Today, we will look at 5 stocks that analysts are highly bullish about in March 2024. Analysts have recently given a Buy ...

Local CF startup raises one of the largest VC rounds in Mass. so far this year

12d ago, source:

A Waltham startup developing new treatments for cystic fibrosis has raised the largest Series C funding round so far in Massachusetts this year.

The Resilience of Monoclonal Antibodies and their Makers

3d ago, source: The Scientist

The road to developing monoclonal antibodies for effectively targeting cancer was paved with tenacity, passion, and strokes ...

Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

12d ago, source:

We are pleased to have Habib take on the role of Chair of the Board,” said Tim Noyes, Chief Executive Officer of Aerovate Therapeutics. “With the Phase 2b data readout from our global IMPAHCT trial of ...

5 Top Dividend Stocks Passive Income Investors Should Buy in March

8d ago, source: 24/7 Wall St on MSN

Investors seeking passive income should consider five quality blue-chip stocks that have paid big, dependable dividends for ...

AstraZeneca acquires Amolyt in $1B deal

4d ago, source: usaherald

AstraZeneca, a pharmaceutical giant, announced on Thursday its acquisition of Amolyt Pharma, a clinical stage biotechnology company, in a deal valued at up to $1.05 billion. This strategic move aims ...

5 Reasons AstraZeneca Stock Can Rise In 2024

10d ago, source:

AstraZeneca's positive revenue guidance, recent approvals, and attractive valuation make it a potential stock to watch. Click ...

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

6d ago, source:

Dr. Louis Aronne is a leading authority on obesity and its treatment. He is the Sanford I. Weill Professor of Metabolic Research and the director of the Comprehensive Weight Control Center, a state-of ...

AstraZeneca to invest 650 million pounds in UK to boost 'pandemic preparedness'

on MSN ago, source:

AstraZeneca plans to invest 650 million pounds ($826.80 million) in Britain to boost research, development and manufacturing of vaccines, the government announced on Wednesday as part of Finance ...

Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States

4d ago, source: Yahoo Finance

in the United States (U.S.) by Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), the Company’s commercialization partner for North America. “Congratulations to our partner Catalyst on the launch of ...

AstraZeneca Announced Further GBP200 Million Investment to Expand Presence in Cambridge

on MSN ago, source:

The government also said AstraZeneca and the U.K. Health Security Agency plan to partner “to advance science for developing ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...